GOSERELIN 3.6mg (Zoladex®)

Clinical Indication

Breast cancer


Zoladex 3.6mg implant is the only licensed product for breast cancer



Local guidance

To be included in the primary care enhanced service for administration

Date of classification

May 2016


Specialist recommendation: Medicines initiated (and stabilised where appropriate) or recommended by a specialist service for prescribing in primary care. Requests should be clearly communicated either through written communication including using approved paperwork if available or verbal means as appropriate .